Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million) in a Series A+ financing round. The investment round was led by SDIC China Merchants Investment, with additional contributions from Huagai Capital, Yuanxi Haihe Fund, and existing investor Trinity Innovation Fund. The funds will be utilized to accelerate the global development of Argo Biopharma’s four clinical pipelines, the discovery of multiple preclinical candidate compounds (PCC), and the enhancement of its modification technology platform and extrahepatic delivery technology platform, as well as to strengthen its professional team.
Global Development and Pipeline Expansion
The proceeds from the Series A+ financing will play a crucial role in ramping up the global development of Argo Biopharma’s clinical pipelines. The company is committed to advancing its drug candidates through various stages of clinical development, with a focus on addressing unmet medical needs in cardiovascular disease, rare diseases, hepatitis B, autoimmune diseases, nervous system disorders, and more.
Clinical Approvals and Company Milestones
Since its founding in 2021, Argo Biopharma has made significant strides, boasting four pipeline candidates at clinical stages and one entering the clinic. The company has received clinical trial approvals in China, the United States, and Australia, marking a significant milestone in its journey to bring innovative siRNA therapies to patients worldwide.-Fineline Info & Tech
